Novo Nordisk and Aspect Biosystems Expand Partnership to Develop Curative Cell Therapies for Diabetes
Key Insights
Novo Nordisk and Aspect Biosystems (search) have entered a new phase of their partnership to develop advanced cellular medicines for diabetes, building on their collaboration since 2023.
Aspect Biosystems (search) has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk and will lead development, manufacturing and commercialization efforts.
The partnership focuses on developing an islet replacement therapy for type 1 diabetes designed to restore blood glucose control without chronic immune suppression.
Novo Nordisk and Aspect Biosystems (search) announced on January 20, 2026, that they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes. The expanded collaboration builds on their existing partnership established in 2023 and represents a significant step toward developing potentially curative therapies for serious diseases.
Strategic Technology Transfer and Leadership Structure
Under the new agreement, Aspect Biosystems (search) has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk. Aspect will lead development, manufacturing and commercialization efforts, while Novo Nordisk retains defined rights to expand its role in later-stage development and commercialization.
The partnership involves integrating select Novo Nordisk cell therapy research, development, and manufacturing capabilities and expertise from the United States and Denmark into Aspect's Canada-anchored platform. This integration is designed to strengthen Aspect's end-to-end capabilities and expand access to highly skilled talent.
Financial Investment and Future Revenue Structure
Novo Nordisk will make an additional equity investment in Aspect and provide research funding to advance these potentially curative therapies. In return, Novo Nordisk will be eligible to receive royalties and milestone payments on future product sales from Aspect.
"Novo Nordisk was founded on a commitment to improve the lives of people living with diabetes. That commitment is as strong now as it was 100 years ago, and we have a continued focus on bringing innovation to people living with type 1 diabetes through internal and external innovation efforts," said Jacob Sten Petersen, senior vice president, Global Research, Novo Nordisk.
Therapeutic Focus and Platform Technology
The partnership specifically targets the development of cellular medicines designed to replace, repair or supplement biological functions to deliver truly disease-modifying therapies. Aspect's platform is being applied to develop a new class of cellular medicines and functional cures for serious metabolic and endocrine diseases.
The lead program focuses on an islet replacement therapy for type 1 diabetes designed to restore blood glucose control without the need for chronic immune suppression. These cellular medicines are designed to be allogeneic, enabling scalable manufacturing using off-the-shelf cells.
"Our partnership with Novo Nordisk combines more than a century of their global leadership in the fight against diabetes with Aspect's leadership in cell therapy and our biotech speed and agility, creating a powerful force multiplier to deliver clinical impact," said Tamer Mohamed, founder and CEO, Aspect Biosystems (search).
Technology Platform Integration
Aspect Biosystems (search) operates a full-stack tissue therapeutic platform that integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. The company is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.
The collaboration reflects both companies' shared mission to accelerate the development of potentially curative medicines for serious diseases, with Petersen noting the partnership's potential to "progress transformative cell therapies toward clinical development and potentially generating a functional cure for people living with diabetes."